Taurin in combined treatment of metabolic syndrome and diabetes mellitus
- Authors: Ametov A.S.1, Kochergina I.I.1, Doskina E.V.1, Abaeva B.S.1, Elizarova E.P.1, Ametov AS2, Kochergina II2, Doskina EV2, Abaeva BS.2, Elizarova EP2
-
Affiliations:
- ГОУ ДПО РМАПО Росздрава
- Russian Academy of Advanced Medical Training
- Issue: Vol 83, No 10 (2011)
- Pages: 31-36
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30917
- ID: 30917
Cite item
Full Text
Abstract
Keywords
About the authors
Aleksandr Sergeevich Ametov
ГОУ ДПО РМАПО Росздравакаф. эндокринологии и диабетологии ГОУ ДПО РМАПО, зав. каф., тел.: 8-499-210-35-04; ГОУ ДПО РМАПО Росздрава
Irina Ivanovna Kochergina
ГОУ ДПО РМАПО Росздрава
Email: kii7@yandex.ru
каф. эндокринологии и диабетологии РМАПО, доц., тел.: 8-499-210-35-08; ГОУ ДПО РМАПО Росздрава
Elena Valer'evna Doskina
ГОУ ДПО РМАПО Росздравакаф. эндокринологии и диабетологии РМАПО, доц., тел.: 8-499-210-35-08; ГОУ ДПО РМАПО Росздрава
Birlant Said-Mukhamedovna Abaeva
ГОУ ДПО РМАПО Росздравакаф. эндокринологии и диабетологии РМАПО, заочный аспирант, тел.: 8-499-210-35-08; ГОУ ДПО РМАПО Росздрава
Evgeniya Pavlovna Elizarova
ГОУ ДПО РМАПО Росздраваканд. биол. наук; ГОУ ДПО РМАПО Росздрава
A S Ametov
Russian Academy of Advanced Medical TrainingRussian Academy of Advanced Medical Training
I I Kochergina
Russian Academy of Advanced Medical TrainingRussian Academy of Advanced Medical Training
E V Doskina
Russian Academy of Advanced Medical TrainingRussian Academy of Advanced Medical Training
B S-M Abaeva
Russian Academy of Advanced Medical TrainingRussian Academy of Advanced Medical Training
E P Elizarova
Russian Academy of Advanced Medical TrainingRussian Academy of Advanced Medical Training
References
- Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
- Ferranini E., Natali A. et al. Insulin resistance, hyperinsulinemia and blood pressure: role of age and obesity. European Group for the study of insulin resistance (EGIR). Hypertension 1997; 30: 1144-1149.
- UKPDS Group. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observation study. Br. Med. J. 2000; 321: 405-413.
- Ackermann D., Hemsen H. A. Hypoglycemic effect of taurine. J. Physiol Chem. 1935; 235: 115-121.
- Michalk D. V., Wingenfeld P., Licht C. H. Protection against cell damage due to hypoxia and reoxygenation: the role of taurine and the involved mechanisms. Amino Acids 1997; 13: 337-346.
- Wu Q. D., Wang J. H., Fennessy F. et al. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am. J. Physiol. 1999; 277; 1229-1238.
- Докшина Г. А., Силаева Т. Ю., Ярцев Е. И. Некоторые инсулиноподобные эффекты таурина. Вопр. мед. химии 1976; 22(1): 503-507.
- Kulakowski Е. С., Maturo J. Hypoglycemic properties of taurine: not mediated by enhanced insulin release. Biochem Pharmacol. 1984; 33(18): 2835-2838.
- Maturo J., Kulakowski E. C. Taurine binding to the purified insulin receptor. Biochem. Pharmacol. 1988; 37(19): 3755- 3760.
- Lee S. H. Enhancing effect of taurine on glucose response in UCP2-overexpressing beta cell. Diabet. Res. Clin. Pract. 2004; 66(suppl. 1): 69-74.
- Di Leo M. A., Santini S. A., Silveri N. G. et al. Lone-term taurine supplementation reduces mortality rate in streptozotocin-induced diabetic rats. Amino Acids 2004; 27(2): 187-191.
- Seghieri G., Tesi F., Bianchi L. et al. Taurine in women with a history of gestational diabetes. Diabet. Res. Clin. Pract. 2006; 3(1): 15-20.
- Zhang M., Bi L. F., Su X. L. et al. Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Gpncircg Toyama, Japan, 2002: 56(2): 97-99.
- Chang L., Xu J., Yu F. et al. Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 2004; 27: 37-48.
- Wharton B. A., Morley C. N., Isaacs E. B. et al. Low plasma taurine and later neurodevelopment. Arch. Dis. Childh. Fetal. Neonatal. Ed. 2004; 89(5): 76-81.
- Sadzuka Y., Matsuura M., Sonobe T. The effect of taurine, a novel biochemical modulator, on the antitumor activity of Doxorubicin. Biol. Pharm. Bull. 2009; 32(9): 1584-1587.
- Nandhini A. T., Thirunavukkarasu V., Anuradha C. V. Stimulation of glucose utilization and inhibition of protein glycation and AGE products by taurine. Acta Physiol. Scand. 2004; 181(3): 297-303.
- Li C., Cao L., Zeng Q. et al. Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type 2 receptor expression. Cardiovasc. Drugs Ther. 2005; 19(2): 105-112.
- Weiss S. J. et al. Chlorination of taurine by human neutrophils. J. Clin. Invest 1982; 70: 598-607.
- Кахновский И. М., Королева Е. В., Захарченко В. Н., Ларионов С. М. Таурин в лечении сахарного диабета. Клин. фармакол. и тер. 1997; 3: 10-12.
- Han J., Bae J. H. et al. Taurine increases glucose sensitivity of UCP2-overexpressing beta-cells by ameliorating mitochondrial metabolism. Am. J. Physiol. Endocrinol. Metab. 2004; 287(5): E1008-E1018.
- Li C., Xu J., Yu F. et al. Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 2004; 27: 37-48.
- Nandhini A. T., Thirunavukkarasu V., Anuradha C. V. Stimulation of glucose utilization and inhibition of protein glycation and AGE products by taurine. Acta Physiol. Scand. 2004; 181(3): 297-303.
- Yamory L. et al. Taurine and cardiac study. Clin. Exp. Pharmacol. Physiol. 2004; 20(1): 15-21.
- Аметов А. С., Кочергина И. И. Применение дибикора при сахарном диабете и сердечно-сосудистой патологии. М.: ПИК ФАРМА; 2009.
- Влияние дибикора на обмен веществ при сахарном диабете типа 1 и 2. М.: ПИК-ФАРМА; 2006.
- Недосугова Л. В., Елизарова Е. П., Балаболкин М. И. Метаболическая терапия сахарного диабета дибикором: новые данные. Лечащий врач 2004; 5: 20-21.
- Глузкер А. А. Таурин в комплексном лечении больных недостаточностью кровообращения IIА стадии: Дис. ... канд. мед. наук. М.; 1998.
- Заволовская Л. И., Елизарова Е. П., Орлов В. А. Клиническая эффективность тауфона в комбинированном лечении больных с хронической недостаточностью кровообращения. Экспер. и клин. фармакол. 1995; 58(2): 29-32.
- Мановицкая А. В. Эффекты дибикора у больных с метаболическим синдромом. Качество жизни. Медицина 2008; 3: 41-46.
- Anthrayose C. V., Shashidhar S. Studies on protein and taurine in normal, senile and diabetic cataractous human lenses. Indian J. Physiol. Pharmacol. 2004; 48(3): 357-360.
- Malone J. I., Lowitt S., Cook W. R. Non-osmotic diabetic cataracts. Pediatr. Res. 1990; 27: 293-296.
![](/img/style/loading.gif)